GEN-MKT-18-7897-A
Aug 10, 2016 | Blogs, Forensic | 0 comments
How do you know what you can’t see? This is the challenge many a lab faces as they relentlessly test for novel psychoactive substances (NPS) as unknown samples with an ever-changing ingredient list make discovery difficult work at best. There are many reasons for the complexities of which you can discover in this application note, “Accurate Mass Screening Workflows for the Analysis of Novel Psychoactive Substances.” However, the biggest of which is that non-targeted findings can turn up thousands of molecular features in a single sample. Sifting through the peaks is laborious, and many are normal besides.
Therefore, in this application note, our researchers took a comparative screening approach to NPS by testing urine samples against a control group using high resolution and accurate mass LC-MS/MS. The TripleTOF® system was then operated in IDA mode to acquire MS and MS/MS information simultaneously.Using this method reduced the compound list from thousands to just 10. Now that is a much more manageable sample size for which to analyze peak findings.
Application Note Overview:
Be confident in your NPS sample. Review the application note in its entirety.Download the Designer Forensic Drug Analysis Solution Kit >
Regulated laboratories are evolving faster than ever. New analytical modalities, higher sample throughput, increasing regulatory scrutiny, and leaner teams are reshaping how work gets done. At the same time, expectations for data integrity, standardization, and operational efficiency continue to increase complexity and/or scope. In this environment, LC-MS software is no longer simply an instrument control platform—it has become a critical part of a laboratory’s quality management system. The question is no longer whether your lab has changed, but whether your software has evolved to support the way regulated labs operate today, and if they are ready and able to meet the demands, they will face tomorrow.
Analyst software has long been a trusted foundation in regulated LC-MS laboratories—and for many, it still performs reliably today. But regulated environments are evolving faster than ever. As labs transition to Windows 11, strengthen cybersecurity policies, modernize IT infrastructure, and prepare for future compliance expectations, software decisions are no longer just about what works today—they’re about managing tomorrow’s risk. Analyst will not be supported on Windows 11. While some labs may continue operating in unsupported environments temporarily, the bigger question is: when that risk becomes reality, will your lab be reacting under pressure—or executing a planned mitigation strategy with confidence?
As regulatory scrutiny increases and detection requirements tighten, laboratories are facing a new question: How can TFA be measured reliably, sensitively, and at scale?
Posted by
You must be logged in to post a comment.
Share this post with your network